Erik Swain is the Executive Editor at Healio Cardiology. He covers a wide range of topics within medicine and healthcare, including alternative medicine, health and wellness, and the healthcare system, with a focus on pressing issues like the coronavirus and the intersection of AI and nutrition. Erik's work has been featured in Medical Device and Diagnostic Industry (MDDI) and Healio.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Erik's coverage primarily focuses on scientific and healthcare topics, specifically cardiovascular health, heart conditions, medical research, medications, and treatment options. His articles heavily rely on cited data to support the content.
Given Erik’s focus on scientific and healthcare topics with a reliance on data citations, he would likely be receptive to pitches from experts who can provide in-depth analysis of new medical research findings or breakthroughs in the field of cardiovascular health. Pitches should highlight access to credible data or studies that support their insights.
Since his geographic focus is not specified but the topics covered are universal issues related to healthcare and medicine, sources with expertise in these areas could reach out regardless of location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Erin T. Welsh Ma
GLP-1 receptor agonists improved clinical outcomes related to kidney and heart health while lowering mortality rates for individuals with diabetes, chronic kidney disease or preexisting cardiovascular disease with overweight or obesity.“GLP-1 receptor agonists not only lower blood glucose levels and body weight, but also have kidney-protective and heart-protective benefits,” Sunil V.
CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.The phase 2 ALPACAR trial, results of which were presented at the American Heart Association Scientific Sessions and simultaneously published in JAMA, included 178 patients (mean age, 63.7 years;
By: Katherine H. Saunders, Erik Swain
SAN ANTONIO — In this Healio video exclusive, Katherine H. Saunders, MD, DABOM , discusses important considerations for appropriate prescription of weight-loss medications.
By: Richard Smith, Erik Swain
CHICAGO — When race was removed from the MESA risk prediction score, its ability to predict risk for heart disease did not change significantly, researchers reported at the American Heart Association Scientific Sessions.
By: Erik Swain, Erin T. Welsh
Key takeaways: Higher greenspace levels in early adolescence were tied to lower adiposity measures in late adolescence.
By: Cassandra Jenkins, Erik Swain
The presence of Type D personality among patients with CAD or their spouses was associated with elevated risk for cardiac events, according to a study published in the European Journal of Preventive Cardiology
By: Richard Smith, Erik Swain
Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by approximately 20% at 1 year in patients with overweight or obesity, according to a presentation.
By: Erik Swain, Richard Smith, Michael Monostra
The field of endocrinology saw many advancements in 2024 and more developments and innovations are anticipated in 2025.
By: Erik Swain, Richard Smith
CHICAGO — Exenatide, an IV GLP-1 receptor agonist , did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.
(833) 317-6278 
